Join
Live feed
·
PRReleasevia Quantisnow
Rapport Therapeutics Inc. logo

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
RAPP· Rapport Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAPP (Rapport Therapeutics Inc.) and more on Quantisnow.